Rossmore Private Capital Has $5.56 Million Position in Merck & Co., Inc. (NYSE:MRK)
Rossmore Private Capital Has $5.56 Million Position in Merck & Co., Inc. (NYSE:MRK)
Rossmore Private Capital lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK – Get Rating) by 3.1% in the first quarter, according to its most recent filing with the SEC. The firm owned 67,703 shares of the company's stock after selling 2,166 shares during the period. Merck & Co., Inc. accounts for 0.9% of Rossmore Private Capital's portfolio, making the stock its 28th largest position. Rossmore Private Capital's holdings in Merck & Co., Inc. were worth $5,555,000 as of its most recent SEC filing.
據Rossmore Private Capital最近提交給美國證券交易委員會的文件顯示，該公司今年第一季度減持默克公司股票3.1%。該公司在此期間出售了2166股後，擁有67,703股該公司的股票。默克公司在Rossmore Private Capital的投資組合中佔0.9%，這使該股成為其第28大頭寸。截至最近提交給美國證券交易委員會的文件，羅斯莫爾私人資本持有的默克公司股份價值555.5萬美元。
Several other institutional investors and hedge funds also recently made changes to their positions in the business. Landmark Wealth Management LLC bought a new position in Merck & Co., Inc. during the first quarter worth about $25,000. Joseph P. Lucia & Associates LLC acquired a new stake in shares of Merck & Co., Inc. in the 1st quarter valued at approximately $25,000. Financial Avengers Inc. boosted its stake in Merck & Co., Inc. by 115.8% during the 4th quarter. Financial Avengers Inc. now owns 328 shares of the company's stock worth $25,000 after acquiring an additional 176 shares during the last quarter. Front Row Advisors LLC grew its holdings in Merck & Co., Inc. by 89.4% during the fourth quarter. Front Row Advisors LLC now owns 339 shares of the company's stock valued at $26,000 after purchasing an additional 160 shares during the period. Finally, Okabena Investment Services Inc. bought a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $27,000. Institutional investors own 72.88% of the company's stock.
其他幾家機構投資者和對衝基金最近也改變了他們在該業務中的頭寸。Landmark Wealth Management LLC在第一季度購買了默克公司(Merck&Co.)的新頭寸，價值約25,000美元。Joseph P.Lucia&Associates LLC在第一季度收購了默克公司價值約2.5萬美元的新股。金融復仇者聯盟第四季度將其在默克公司的持股比例提高了115.8%。金融復仇者聯盟現在持有328股該公司股票，價值25,000美元，在上個季度增持了176股。Front Row Advisors LLC在第四季度增持了默克公司89.4%的股份。Front Row Advisors LLC在此期間又購買了160股，現在擁有339股該公司股票，價值2.6萬美元。最後，Okabena Investment Services Inc.在第四季度購入默克公司新的股份，價值約27,000美元。機構投資者持有該公司72.88%的股票。
Merck & Co., Inc. Stock Up 0.7 %
默克公司股價上漲0.7%
NYSE:MRK opened at $87.41 on Friday. Merck & Co., Inc. has a twelve month low of $70.89 and a twelve month high of $95.72. The firm has a market capitalization of $221.04 billion, a price-to-earnings ratio of 13.39, a price-to-earnings-growth ratio of 1.18 and a beta of 0.32. The company has a quick ratio of 1.14, a current ratio of 1.40 and a debt-to-equity ratio of 0.75. The stock's 50 day moving average price is $90.27 and its two-hundred day moving average price is $85.41.
紐約證券交易所：Mr K上週五開盤報87.41美元。默克公司股價跌至70.89美元的12個月低點和95.72美元的12個月高點。該公司市值為2,210.4億美元，市盈率為13.39倍，市盈率為1.18倍，貝塔係數為0.32。該公司的速動比率為1.14，流動比率為1.40，債務權益比為0.75。該股的50日移動均線價格為90.27美元，200日移動均線價格為85.41美元。
Merck & Co., Inc. Announces Dividend
默克公司宣佈分紅
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be issued a dividend of $0.69 per share. This represents a $2.76 dividend on an annualized basis and a yield of 3.16%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.'s payout ratio is currently 42.27%.
該公司最近還宣佈了季度股息，將於10月7日星期五支付。9月15日(星期四)登記在冊的投資者將獲得每股0.69美元的股息。這意味着年化股息為2.76美元，收益率為3.16%。本次股息除息日為9月14日星期三。默克公司目前的派息率為42.27%。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
A number of brokerages have recently weighed in on MRK. Cowen lifted their price target on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a "market perform" rating in a research report on Monday, June 27th. Barclays boosted their target price on Merck & Co., Inc. from $94.00 to $97.00 and gave the company an "overweight" rating in a research note on Tuesday, April 12th. Mizuho began coverage on Merck & Co., Inc. in a research report on Friday, June 24th. They set a "buy" rating and a $100.00 price target on the stock. Morgan Stanley increased their target price on Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an "equal weight" rating in a research note on Friday, July 29th. Finally, UBS Group lifted their price target on shares of Merck & Co., Inc. from $76.00 to $98.00 and gave the company a "neutral" rating in a research note on Monday, July 18th. Eight research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and a consensus price target of $97.44.
最近，許多券商都加入了對MRK的看法。考恩在6月27日週一的一份研究報告中將默克公司的股票目標價從95美元上調至102.00美元，並給予該股“市場表現”評級。4月12日，巴克萊銀行在一份研究報告中將默克公司的目標價從94.00美元上調至97.00美元，並給予該公司“增持”評級。瑞穗在6月24日星期五的一份研究報告中開始對默克公司進行報道。他們為該股設定了“買入”評級和100.00美元的目標價。摩根士丹利在7月29日星期五的一份研究報告中將默克公司的目標價從88.00美元上調至92.00美元，並給予該股“同等權重”的評級。最後，瑞銀集團在7月18日星期一的一份研究報告中將默克公司的股票目標價從76.00美元上調至98.00美元，並給予該公司“中性”評級。8名研究分析師對該股的評級為持有，9名分析師給出了買入評級，兩名分析師對該公司股票給予了強烈的買入評級。根據MarketBeat.com的數據，默克公司的共識評級為“適度買入”，共識目標價為97.44美元。
Merck & Co., Inc. Company Profile
默克公司公司簡介
(Get Rating)
(獲取評級)
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
默克公司是一家全球性的醫療保健公司。它通過兩個部門運作，製藥和動物健康。製藥部門提供腫瘤學、醫院急性護理、免疫學、神經科學、病毒學、心血管和糖尿病等領域的人類健康藥物產品，以及疫苗產品，如預防性兒科、青少年和成人疫苗。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Merck & Co., Inc. (MRK)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- 免費獲取StockNews.com關於默克公司的研究報告(MRK)
- MarketBeat：回顧中的一週8/1-8/5
- 如何利用高貝塔係數股票最大化你的投資利潤
- 克羅諾斯集團(Cronos Group Inc.)營收上升，是時候收購了嗎？
- 蘋果為何可能在年底創下歷史新高
- Beyond Meat不是沒有希望，而且它很便宜
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到默克公司的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對默克公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。